Related Experiment Videos
CYP1A2 activity as a risk factor for bladder cancer
1Department of Urology, Seoul National University College of Medicine, Korea.
Journal of Korean Medical Science
|December 1, 1994
Summary
Individuals with higher CYP1A2 activity, indicated by theophylline metabolism, face an increased risk of developing urinary bladder cancer. This metabolic capacity is a significant factor in nonoccupational bladder cancer development.
Area of Science:
- Pharmacogenomics
- Oncology
- Metabolism
Background:
- Urinary bladder cancer risk is influenced by genetic and environmental factors.
- Enzyme activity, particularly cytochrome P450 enzymes, plays a role in carcinogen metabolism.
Purpose of the Study:
- To investigate the association between specific drug-metabolizing enzyme activities and bladder cancer risk.
- To determine if CYP1A2, CYP2D6, or N-acetyltransferase activity is a significant risk factor.
Main Methods:
- Enzyme activities were measured in 100 bladder cancer patients and 84 controls using theophylline, metoprolol, and isoniazid.
- Urinary metabolite levels were quantified to estimate CYP1A2, CYP2D6, and N-acetyltransferase activity.
- Logistic regression analysis was performed to identify independent risk factors.
Main Results:
- No significant differences were found in N-acetyltransferase or CYP2D6 activity between patients and controls.
- A significantly higher recovery ratio of 1-methyluric acid from theophylline (reflecting CYP1A2 activity) was observed in bladder cancer patients.
- The 1-methyluric acid recovery ratio was identified as an independent risk factor for bladder cancer.
Conclusions:
- Increased CYP1A2 activity, specifically the 3-demethylation of theophylline, is significantly associated with an elevated risk of nonoccupational urinary bladder cancer.
- CYP1A2 activity is a potential biomarker for bladder cancer risk assessment.